

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

**POLL RESULTS OF EXTRAORDINARY GENERAL MEETING
HELD ON 2 FEBRUARY 2026**

The Board is pleased to announce that the resolutions proposed at the EGM held on 2 February 2026 were duly passed by the Shareholders by way of poll.

References are made to the notice of the extraordinary general meeting and circular (the “**Circular**”) of China Traditional Chinese Medicine Holdings Co. Limited dated 15 January 2026. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that the EGM was held on 2 February 2026 and the resolutions proposed at the EGM were duly passed by the Shareholders by way of poll.

As at the date of the EGM, there were a total of 5,035,801,852 Shares in issue, which was the total number of eligible Shares that entitled the Shareholders to attend and vote for or against the resolutions at the EGM. CNPGC and its associates, who were interested in 1,685,055,642 Shares as at the date of the EGM (representing approximately 33.46% of the total issued Shares), have abstained from voting on the relevant resolutions at the EGM. Save for the above, no Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the resolutions at the EGM. There were no Shares entitling the holders to attend and abstain from voting in favour of the resolutions at the EGM as set out in Rule 13.40 of the Listing Rules.

The poll results in respect of the resolutions were as follows:

Ordinary resolutions	No. of votes cast and percentage of total no. of votes cast		Total no. of votes cast
	For	Against	
1. To approve, confirm and ratify the Financial Services (2026-2028) Framework Agreement, the transactions thereunder and the annual caps for the three years ending 31 December 2028 as set out in ordinary resolution No. 1 in the notice convening the EGM.	731,795,341 (75.904722%)	232,301,915 (24.095278%)	964,097,256
2. To approve, confirm and ratify the Master Purchase (2026-2028) Agreement, the transactions thereunder and the annual caps for the three years ending 31 December 2028 as set out in ordinary resolution No. 2 in the notice convening the EGM.	953,619,256 (98.999642%)	9,636,000 (1.000358%)	963,255,256
3. To approve, confirm and ratify the Master Supply (2026-2028) Agreement, the transactions thereunder and the annual caps for the three years ending 31 December 2028 as set out in ordinary resolution No. 3 in the notice convening the EGM.	953,529,256 (98.999548%)	9,636,003 (1.000452%)	963,165,259

As more than 50% of the votes were cast in favour of the above resolutions, the resolutions proposed at the EGM were duly passed as ordinary resolutions of the Company.

The executive Directors, Mr. YANG Jun, Mr. LI Hongjian and Mr. PENG Li; the non-executive Directors, Mr. LI Xiangrong, Mr. ZU Jing and Mr. HUANG Hao; and the independent non-executive Directors, Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong attended the EGM either in person or by electronic means. The non-executive Directors, namely Mr. LIU Haijian and Ms. XU Jinghui did not attend the EGM due to other business commitments.

Computershare Hong Kong Investor Services Limited, the share registrar of the Company, was appointed as the scrutineer for the purpose of counting the votes at the EGM.

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
YANG Jun
Chairman

Hong Kong, 2 February 2026

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. YANG Jun, Mr. LI Hongjian and Mr. PENG Li are executive Directors; Mr. LIU Haijian, Mr. LI Xiangrong, Mr. ZU Jing, Ms. XU Jinghui and Mr. HUANG Hao are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.